CALL FOR PAPERS

CERTIFICATE

IMPACT FACTOR 2018

Subject Area

  • Life Sciences / Biology
  • Architecture / Building Management
  • Asian Studies
  • Business & Management
  • Chemistry
  • Computer Science
  • Economics & Finance
  • Engineering / Acoustics
  • Environmental Science
  • Agricultural Sciences
  • Pharmaceutical Sciences
  • General Sciences
  • Materials Science
  • Mathematics
  • Medicine
  • Nanotechnology & Nanoscience
  • Nonlinear Science
  • Chaos & Dynamical Systems
  • Physics
  • Social Sciences & Humanities

Why Us? >>

  • Open Access
  • Peer Reviewed
  • Rapid Publication
  • Life time hosting
  • Free promotion service
  • Free indexing service
  • More citations
  • Search engine friendly

Plagiarism Detection

IJCR is following an instant policy on rejection those received papers with plagiarism rate of more than 20%. So, All of authors and contributors must check their papers before submission to making assurance of following our anti-plagiarism policies.

The effect of troglitazone on coagulation markers among individuals with prediabetes

Author: 
Khalid Mokhtar, MS, Pharm D., Elgenaid Hamadain, Hamed Benghuzzi, 2Michelle Tucci, Kenneth Butler, Ibrahim Jamil, Donna Sullivan, and Felicia Tardy
Subject Area: 
Health Sciences
Abstract: 

The present work is focused on coagulation defects associated with prediabetes, which are reflected in laboratory abnormalities of coagulation markers, such as fibrinogen and tPA. These markers are associated with increased risks of thrombosis which are associated with increased risks of cardiovascular (CV) events, including myocardial infarction (MI), coronary heart disease (CHD), and other forms of atherosclerosis. The Diabetes Prevention Program (DPP) trial was designed to study the effect of four different interventions (Intensive Lifestyle (ILS) modifications, metformin, troglitazone, and placebo) on the development and progression of diabetes in subjects with Impaired glucose tolerance (IGT). In this study we analyzed the effect of troglitazone on coagulation markers including fibrinogen and tPA in the DPP population. Materials and Methods: Our analysis selected a subgroup (n= 3,171) from the original DPP population. The effect of troglitazone on coagulation markers was measured by analyzing its effects on the levels of fibrinogen and tPA at baseline and at 12 months and compared to the other three interventions (ILS, metformin, and placebo). Results: Troglitazone reduced fibrinogen levels, median percent change of - 6.65% (p <0.001) for all between group analysis: troglitazone vs. lifestyle, troglitazone vs. metformin, and troglitazone vs. placebo). This change revealed the highest change among all other interventions as reported in the previous DPP studies. Troglitazone also produced the highest median percent reduction in tPA levels (-21.39%) comparted to -20.41% in the lifestyle, -18.00% in the metformin, and -6.25% in the placebo intervention. Discussion and Conclusions: Our study demonstrated the benefits of the TZDs in reducing certain CV surrogate risk markers due to the treatment with troglitazone for 12 months. These benefits appeared as a decrease in the levels of coagulation markers including fibrinogen and tPA. These benefits are of special value especially in such a population already at increased risk for CV morbidity and mortality. The effects of troglitazone on these markers exceed that of metformin. Our analysis was unable to associate the effect of changes in weigh and waist circumference, and changes in measures of glycemia and insulin resistance with the main effect of troglitazone on coagulation markers.

PDF file: 

IJMCE RECOMMENDATION

ONLINE PAYPAL PAYMENT

CURRENT ISSUE

NEWS

CHIEF EDITOR
Rosane Cavalcante Fragoso, Brasil
ASSOCIATE CHIEF EDITOR

   

Jean-Marc SABATIER
Chief Scientific Officer and Head of a Research Group
France

Advantages of IJCR

  • Rapid Publishing
  • Professional publishing practices
  • Indexing in leading database
  • High level of citation
  • High Qualitiy reader base
  • High level author suport

EDITORIAL BOARD

Luai Farhan Zghair
Iraq
Hasan Ali Abed Al-Zu’bi
Jordanian
Fredrick OJIJA
Tanzanian
Firuza M. Tursunkhodjaeva
Uzbekistan
Faraz Ahmed Farooqi
Saudi Arabia
Eric Randy Reyes Politud
Philippines
Elsadig Gasoom FadelAlla Elbashir
Sudan
Eapen, Asha Sarah
United State
Dr.Arun Kumar A
India
Dr. Zafar Iqbal
Pakistan
Dr. SHAHERA S.PATEL
India
Dr. Ruchika Khanna
India
Dr. Recep TAS
Turkey
Dr. Rasha Ali Eldeeb
Egypt
Dr. Pralhad Kanhaiyalal Rahangdale
India
DR. PATRICK D. CERNA
Philippines
Dr. Nicolas Padilla- Raygoza
Mexico
Dr. Mustafa Y. G. Younis
Libiya
Dr. Muhammad shoaib Ahmedani
Saudi Arabia
DR. MUHAMMAD ISMAIL MOHMAND
United State
DR. MAHESH SHIVAJI CHAVAN
India
DR. M. ARUNA
India
Dr. Lim Gee Nee
Malaysia
Dr. Jatinder Pal Singh Chawla
India
DR. IRAM BOKHARI
Pakistan
Dr. FARHAT NAZ RAHMAN
Pakistan
Dr. Devendra kumar Gupta
India
Dr. ASHWANI KUMAR DUBEY
India
Dr. Ali Seidi
Iran
Dr. Achmad Choerudin
Indonesia
Dr Ashok Kumar Verma
India
Thi Mong Diep NGUYEN
France
Dr. Muhammad Akram
Pakistan
Dr. Imran Azad
Oman
Dr. Meenakshi Malik
India
Aseel Hadi Hamzah
Iraq
Anam Bhatti
Malaysia
Md. Amir Hossain
Bangladesh
Ahmet İPEKÇİ
Turkey
Mirzadi Gohari
Iran